These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
463 related items for PubMed ID: 19667589
1. Meeting the challenge of antibiotic resistance: The PROTEKT US study. Stratton CW. Postgrad Med; 2002 Sep; 112(3 Suppl):7-11. PubMed ID: 19667589 [Abstract] [Full Text] [Related]
9. Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001. Waites K, Brown S. South Med J; 2003 Oct 01; 96(10):974-85. PubMed ID: 14570341 [Abstract] [Full Text] [Related]
10. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections? Carter PL. Postgrad Med; 2002 Sep 01; 112(3 Suppl):18-25. PubMed ID: 19667591 [Abstract] [Full Text] [Related]
11. What can PROTEKT tell us at a local level? Inoue M. J Chemother; 2002 Jul 01; 14 Suppl 3():17-24. PubMed ID: 12418557 [Abstract] [Full Text] [Related]
12. Barriers to the effective management of respiratory tract infections in the community. Saginur R. Infection; 2001 Dec 01; 29 Suppl 2():3-10. PubMed ID: 11785853 [Abstract] [Full Text] [Related]
13. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance. Rapp RP. Postgrad Med; 2002 Sep 01; 112(3 Suppl):12-7. PubMed ID: 19667590 [Abstract] [Full Text] [Related]
14. Get a handle on resistance before it gets a handle on you: the PROTEKT US Surveillance Study. Prospective Resistant Organism Tracking and Epidemiology for Ketolide Telithromycin. Stratton CW. South Med J; 2001 Sep 01; 94(9):891-2. PubMed ID: 11592749 [No Abstract] [Full Text] [Related]
15. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000). Kohno S, Hoban D, Protekt Surveillance Study Group. J Chemother; 2003 Aug 01; 15(4):335-41. PubMed ID: 12962361 [Abstract] [Full Text] [Related]
17. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study. Farrell DJ, File TM, Jenkins SG. J Clin Microbiol; 2007 Feb 01; 45(2):290-3. PubMed ID: 17093012 [Abstract] [Full Text] [Related]
19. Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000). Felmingham D, Farrell DJ, Reinert RR, Morrissey I. J Infect; 2004 Jan 01; 48(1):39-55. PubMed ID: 14667791 [Abstract] [Full Text] [Related]
20. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. Brown SD, Farrell DJ. J Antimicrob Chemother; 2004 Aug 01; 54 Suppl 1():i23-9. PubMed ID: 15265833 [Abstract] [Full Text] [Related] Page: [Next] [New Search]